Compare DexCom, Inc. (DXCM) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kimberly Clark Corp — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Kimberly Clark Corp trades at $109 (market cap $35.36B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays a 4.81% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KMB | |
|---|---|---|
Market Cap | $28.06B | $35.36B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $136.77 |
52-Week Low | $54.84 | $93.05 |
Enterprise Value | $27.03B | $41.90B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Kimberly-Clark (KMB) trades at $106.82, down 3.05% on the day, near the analyst low target of $106.00. The stock shows a bullish technical signal with RSI at 24.78 indicating potential oversold conditions, while recent quarterly EPS beats and a 4.5% dividend yield highlight fundamental strength. The company's pending Kenvue acquisition and innovation-driven growth strategy are key developments, though revenue declined to $16.45B in 2025 from $20.1B in 2024.
KMB offers a stable income play with consistent dividend payments, but investors face risks from high payout ratios and competitive pressures. Analyst consensus is mixed with 32% buy ratings, suggesting cautious optimism. Near-term performance hinges on Q2 2026 earnings due August 4, 2026, with margins under scrutiny amid input cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
